Vaccine Market By Technology Type (Recombinant, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, and Other), Indication (Pneumococcal Disease, Influenza, Human Papilloma Virus, Meningococcal Disease, Rotavirus, Varicella, Measles, Mumps, & Rubella, Diphtheria, Pertussis, & Tetanus, Polio, Hepatitis and Other) and End User (Pediatric, Adult and Traveler) and Geography – Global Forecast up to 2027
The Vaccines Market is estimated to grow at the rate of 6.7% CAGR by 2027. The key factors accelerating the vaccine market are the high incidence of diseases requiring vaccines and increasing use of vaccines in preventing the number of infectious diseases, such as influenza, pneumonia, and rotavirus infection. Moreover, the focus of governments on immunization programs further helps promote awareness among people about the safety and availability of vaccines. Another factor accelerating the market growth is various technologies deployed in the development of effective vaccines. However, the time taken for the development and introduction of the vaccine impedes the market growth. Vaccines also referred to as immunizations, are a weakened form of a disease administered into the body to generate antibodies against the disease. Effectual immunization has destroyed several diseases, such as polio and smallpox, with high death rates. Vaccinations have a prominent role in maintaining sustainable health among people in many countries; hence, they are embraced in many regional disease-prevention strategies.
Vaccines Market based on Technology Type
The market is further segmented based on the indication, in which diphtheria, pertussis, & tetanus segment hold a significant share in the market. The foremost share of this segment is attributed to the increasing number of cases of these diseases because of the increasing geriatric population and an increasing number of birth rates where these diseases are most likely to affect.
As per the market by end-user, the market is bifurcated into pediatrics, adults, and travelers. The pediatric segment has held a substantial share in the market, owing to the huge demand for vaccines among infants such as MMR vaccines, BCG vaccines, and DPT vaccines since infants are more prone to diseases where vaccines are mainly required.
According to the geographical market, the market is divided into North America, Europe, Asia Pacific, and the rest of the world. The North American region is registered for the largest share in the market. This is due to the high incidence of infectious diseases and rising investments by government and non-government organizations for vaccine development in the region.
In the present era, there are growing concerns about the spread of infectious diseases with the changing environment worldwide. These rising infectious diseases are pressure on public health but also affect global economies. The new diseases such as HIV, hepatitis, dengue have drawn considerable concern for the government of the respective countries. There is also an upturn of diseases assumed to be under control, such as malaria, cholera, and many more. Thus the rising number of dreadful infectious diseases and upturn of the diseases are creating a major growth in the vaccines market.
This report includes the company profiles of the Panacea Biotec Limited, Johnson & Johnson Services, Inc, VBI Vaccines Inc., Merck & Co., Inc., Astellas Pharma Inc., GlaxoSmithKline Plc, Sanofi S.A., PFIZER INC, NOVAVAX, INC., and Bavarian Nordic.
As a result, vaccines have emerged as an effective solution for the rising infectious diseases worldwide. Various governments of several countries are substantially investing in developing effective vaccines for a surging number of diseases worldwide.
Vaccines Market based on Technology Type
- Recombinant
- Conjugate Vaccines
- Live Attenuated Vaccines
- Inactivated Vaccines
- Toxoid Vaccines
- Others
- Pneumococcal Disease
- Influenza
- Human Papilloma Virus
- Meningococcal Disease
- Rotavirus
- Varicella, Measles, Mumps, & Rubella
- Diphtheria, Pertussis, & Tetanus
- Polio
- Hepatitis
- Other
- Pediatric
- Adults
- Travelers
- North America
- Europe
- Asia Pacific
- Rest of the World
The market is further segmented based on the indication, in which diphtheria, pertussis, & tetanus segment hold a significant share in the market. The foremost share of this segment is attributed to the increasing number of cases of these diseases because of the increasing geriatric population and an increasing number of birth rates where these diseases are most likely to affect.
As per the market by end-user, the market is bifurcated into pediatrics, adults, and travelers. The pediatric segment has held a substantial share in the market, owing to the huge demand for vaccines among infants such as MMR vaccines, BCG vaccines, and DPT vaccines since infants are more prone to diseases where vaccines are mainly required.
According to the geographical market, the market is divided into North America, Europe, Asia Pacific, and the rest of the world. The North American region is registered for the largest share in the market. This is due to the high incidence of infectious diseases and rising investments by government and non-government organizations for vaccine development in the region.
In the present era, there are growing concerns about the spread of infectious diseases with the changing environment worldwide. These rising infectious diseases are pressure on public health but also affect global economies. The new diseases such as HIV, hepatitis, dengue have drawn considerable concern for the government of the respective countries. There is also an upturn of diseases assumed to be under control, such as malaria, cholera, and many more. Thus the rising number of dreadful infectious diseases and upturn of the diseases are creating a major growth in the vaccines market.
This report includes the company profiles of the Panacea Biotec Limited, Johnson & Johnson Services, Inc, VBI Vaccines Inc., Merck & Co., Inc., Astellas Pharma Inc., GlaxoSmithKline Plc, Sanofi S.A., PFIZER INC, NOVAVAX, INC., and Bavarian Nordic.
As a result, vaccines have emerged as an effective solution for the rising infectious diseases worldwide. Various governments of several countries are substantially investing in developing effective vaccines for a surging number of diseases worldwide.
- Several factors are presented in this report which are influencing the market growth and limiting the market.
- This report covers the segmentation and sub-segmentations and their contribution to the market's growth.
- The report includes profiles of the key competitors in the vaccine market and their strategies such as product launches, company expansions, and acquisitions.
- Further, the penetration of the market in the various countries is also depicted in this report.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TECHNOLOGY TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Recombinant
5.3. Conjugate Vaccines
5.4. Live Attenuated Vaccines
5.5. Inactivated Vaccines
5.6. Toxoid Vaccines
5.7. Others
6. INDICATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Pneumococcal Disease
6.3. Influenza
6.4. Human Papilloma Virus
6.5. Meningococcal Disease
6.6. Rotavirus
6.7. Varicella, Measles, Mumps, & Rubella
6.8. Diphtheria, Pertussis, & Tetanus
6.9. Polio
6.10. Hepatitis
6.11. Other
7. END-USER: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Pediatric
7.3. Adults
7.4. Travelers
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. Panacea Biotec Limited
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Johnson & Johnson Services, Inc
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. VBI Vaccines Inc.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Merck & Co., Inc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Astellas Pharma Inc.
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. GlaxoSmithKline Plc
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Sanofi S.A.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. PFIZER INC
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. NOVAVAX, INC.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Bavarian Nordic
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. TECHNOLOGY TYPE: MARKET SIZE & ANALYSIS
5.1. Overview
5.2. Recombinant
5.3. Conjugate Vaccines
5.4. Live Attenuated Vaccines
5.5. Inactivated Vaccines
5.6. Toxoid Vaccines
5.7. Others
6. INDICATION: MARKET SIZE & ANALYSIS
6.1. Overview
6.2. Pneumococcal Disease
6.3. Influenza
6.4. Human Papilloma Virus
6.5. Meningococcal Disease
6.6. Rotavirus
6.7. Varicella, Measles, Mumps, & Rubella
6.8. Diphtheria, Pertussis, & Tetanus
6.9. Polio
6.10. Hepatitis
6.11. Other
7. END-USER: MARKET SIZE & ANALYSIS
7.1. Overview
7.2. Pediatric
7.3. Adults
7.4. Travelers
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. Panacea Biotec Limited
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. Johnson & Johnson Services, Inc
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. VBI Vaccines Inc.
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. Merck & Co., Inc.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. Astellas Pharma Inc.
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. GlaxoSmithKline Plc
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. Sanofi S.A.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. PFIZER INC
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. NOVAVAX, INC.
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. Bavarian Nordic
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL VACCINES MARKET VALUE FOR RECOMBINANT, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL VACCINES MARKET VALUE FOR CONJUGATE VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL VACCINES MARKET VALUE FOR LIVE ATTENUATED VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL VACCINES MARKET VALUE FOR INACTIVATED VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL VACCINES MARKET VALUE FOR TOXOID VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL VACCINES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL VACCINES MARKET VALUE, BY INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL VACCINES MARKET VALUE FOR PNEUMOCOCCAL DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL VACCINES MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL VACCINES MARKET VALUE FOR HUMAN PAPILLOMAVIRUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL VACCINES MARKET VALUE FOR MENINGOCOCCAL DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. GLOBAL VACCINES MARKET VALUE FOR ROTAVIRUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 14. GLOBAL VACCINES MARKET VALUE FOR VARICELLA, MEASLES, MUMPS, & RUBELLA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 15. GLOBAL VACCINES MARKET VALUE FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 16. GLOBAL VACCINES MARKET VALUE FOR POLIO, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 17. GLOBAL VACCINES MARKET VALUE FOR HEPATITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 18. GLOBAL VACCINES MARKET VALUE FOR OTHER, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 19. GLOBAL VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 20. GLOBAL VACCINES MARKET VALUE FOR PEDIATRIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 21. GLOBAL VACCINES MARKET VALUE FOR ADULTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 22. GLOBAL VACCINES MARKET VALUE FOR TRAVELERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 23. NORTH AMERICA VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 24. NORTH AMERICA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 25. NORTH AMERICA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 26. NORTH AMERICA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 27. U.S VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 28. U.S VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 29. U.S VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 30. CANADA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 31. CANADA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 32. CANADA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 33. EUROPE VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 34. EUROPE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 35. EUROPE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 36. EUROPE VACCINES MARKET VALUE, END-USER, 2021-2027 (USD BILLION)
TABLE 37. GERMANY VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 38. GERMANY VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 39. GERMANY VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 40. U.K VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 41. U.K VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 42. U.K VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 43. FRANCE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 44. FRANCE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 45. FRANCE VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 46. ITALY VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 47. ITALY VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 48. ITALY VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 49. SPAIN VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 50. SPAIN VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 51. SPAIN VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 52. ROE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 53. ROE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 54. ROE VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 55. ASIA PACIFIC VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 56. ASIA PACIFIC VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 57. ASIA PACIFIC VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 58. ASIA PACIFIC VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 59. CHINA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 60. CHINA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 61. CHINA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 62. INDIA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 63. INDIA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 64. INDIA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 65. JAPAN VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 66. JAPAN VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 67. JAPAN VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 68. REST OF APAC VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 69. REST OF APAC VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 70. REST OF APAC VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 71. REST OF WORLD VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 72. REST OF WORLD VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 73. REST OF WORLD VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 74. PANACEA BIOTEC LIMITED: FINANCIALS
TABLE 75. PANACEA BIOTEC LIMITED: PRODUCTS & SERVICES
TABLE 76. PANACEA BIOTEC LIMITED: RECENT DEVELOPMENTS
TABLE 77. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS
TABLE 78. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES
TABLE 79. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS
TABLE 80. VBI VACCINES INC: FINANCIALS
TABLE 81. VBI VACCINES INC: PRODUCTS & SERVICES
TABLE 82. VBI VACCINES INC: RECENT DEVELOPMENTS
TABLE 83. MERCK & CO., INC: FINANCIALS
TABLE 84. MERCK & CO., INC: PRODUCTS & SERVICES
TABLE 85. MERCK & CO., INC: RECENT DEVELOPMENTS
TABLE 86. ASTELLAS PHARMA INC: FINANCIALS
TABLE 87. ASTELLAS PHARMA INC: PRODUCTS & SERVICES
TABLE 88. ASTELLAS PHARMA INC: RECENT DEVELOPMENTS
TABLE 89. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 90. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 91. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 92. SANOFI S.A.: FINANCIALS
TABLE 93. SANOFI S.A.: PRODUCTS & SERVICES
TABLE 94. SANOFI S.A.: RECENT DEVELOPMENTS
TABLE 95. PFIZER INC: FINANCIALS
TABLE 96. PFIZER INC: PRODUCTS & SERVICES
TABLE 97. PFIZER INC: RECENT DEVELOPMENTS
TABLE 98. NOVAVAX, INC: FINANCIALS
TABLE 99. NOVAVAX, INC: PRODUCTS & SERVICES
TABLE 100. NOVAVAX, INC: RECENT DEVELOPMENTS
TABLE 101. BAVARIAN NORDIC: FINANCIALS
TABLE 102. BAVARIAN NORDIC: PRODUCTS & SERVICES
TABLE 103. BAVARIAN NORDIC: RECENT DEVELOPMENTS
TABLE 1. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL VACCINES MARKET VALUE FOR RECOMBINANT, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL VACCINES MARKET VALUE FOR CONJUGATE VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL VACCINES MARKET VALUE FOR LIVE ATTENUATED VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL VACCINES MARKET VALUE FOR INACTIVATED VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL VACCINES MARKET VALUE FOR TOXOID VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL VACCINES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL VACCINES MARKET VALUE, BY INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL VACCINES MARKET VALUE FOR PNEUMOCOCCAL DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL VACCINES MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL VACCINES MARKET VALUE FOR HUMAN PAPILLOMAVIRUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL VACCINES MARKET VALUE FOR MENINGOCOCCAL DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. GLOBAL VACCINES MARKET VALUE FOR ROTAVIRUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 14. GLOBAL VACCINES MARKET VALUE FOR VARICELLA, MEASLES, MUMPS, & RUBELLA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 15. GLOBAL VACCINES MARKET VALUE FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 16. GLOBAL VACCINES MARKET VALUE FOR POLIO, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 17. GLOBAL VACCINES MARKET VALUE FOR HEPATITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 18. GLOBAL VACCINES MARKET VALUE FOR OTHER, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 19. GLOBAL VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 20. GLOBAL VACCINES MARKET VALUE FOR PEDIATRIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 21. GLOBAL VACCINES MARKET VALUE FOR ADULTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 22. GLOBAL VACCINES MARKET VALUE FOR TRAVELERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 23. NORTH AMERICA VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 24. NORTH AMERICA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 25. NORTH AMERICA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 26. NORTH AMERICA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 27. U.S VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 28. U.S VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 29. U.S VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 30. CANADA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 31. CANADA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 32. CANADA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 33. EUROPE VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 34. EUROPE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 35. EUROPE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 36. EUROPE VACCINES MARKET VALUE, END-USER, 2021-2027 (USD BILLION)
TABLE 37. GERMANY VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 38. GERMANY VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 39. GERMANY VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 40. U.K VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 41. U.K VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 42. U.K VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 43. FRANCE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 44. FRANCE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 45. FRANCE VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 46. ITALY VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 47. ITALY VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 48. ITALY VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 49. SPAIN VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 50. SPAIN VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 51. SPAIN VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 52. ROE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 53. ROE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 54. ROE VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 55. ASIA PACIFIC VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 56. ASIA PACIFIC VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 57. ASIA PACIFIC VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 58. ASIA PACIFIC VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 59. CHINA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 60. CHINA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 61. CHINA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 62. INDIA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 63. INDIA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 64. INDIA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 65. JAPAN VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 66. JAPAN VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 67. JAPAN VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 68. REST OF APAC VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 69. REST OF APAC VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 70. REST OF APAC VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 71. REST OF WORLD VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
TABLE 72. REST OF WORLD VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
TABLE 73. REST OF WORLD VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
TABLE 74. PANACEA BIOTEC LIMITED: FINANCIALS
TABLE 75. PANACEA BIOTEC LIMITED: PRODUCTS & SERVICES
TABLE 76. PANACEA BIOTEC LIMITED: RECENT DEVELOPMENTS
TABLE 77. JOHNSON & JOHNSON SERVICES, INC: FINANCIALS
TABLE 78. JOHNSON & JOHNSON SERVICES, INC: PRODUCTS & SERVICES
TABLE 79. JOHNSON & JOHNSON SERVICES, INC: RECENT DEVELOPMENTS
TABLE 80. VBI VACCINES INC: FINANCIALS
TABLE 81. VBI VACCINES INC: PRODUCTS & SERVICES
TABLE 82. VBI VACCINES INC: RECENT DEVELOPMENTS
TABLE 83. MERCK & CO., INC: FINANCIALS
TABLE 84. MERCK & CO., INC: PRODUCTS & SERVICES
TABLE 85. MERCK & CO., INC: RECENT DEVELOPMENTS
TABLE 86. ASTELLAS PHARMA INC: FINANCIALS
TABLE 87. ASTELLAS PHARMA INC: PRODUCTS & SERVICES
TABLE 88. ASTELLAS PHARMA INC: RECENT DEVELOPMENTS
TABLE 89. GLAXOSMITHKLINE PLC: FINANCIALS
TABLE 90. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES
TABLE 91. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
TABLE 92. SANOFI S.A.: FINANCIALS
TABLE 93. SANOFI S.A.: PRODUCTS & SERVICES
TABLE 94. SANOFI S.A.: RECENT DEVELOPMENTS
TABLE 95. PFIZER INC: FINANCIALS
TABLE 96. PFIZER INC: PRODUCTS & SERVICES
TABLE 97. PFIZER INC: RECENT DEVELOPMENTS
TABLE 98. NOVAVAX, INC: FINANCIALS
TABLE 99. NOVAVAX, INC: PRODUCTS & SERVICES
TABLE 100. NOVAVAX, INC: RECENT DEVELOPMENTS
TABLE 101. BAVARIAN NORDIC: FINANCIALS
TABLE 102. BAVARIAN NORDIC: PRODUCTS & SERVICES
TABLE 103. BAVARIAN NORDIC: RECENT DEVELOPMENTS
LIST OF FIGURES
CHART. 1. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 2. GLOBAL VACCINES MARKET VALUE FOR RECOMBINANT, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 3. GLOBAL VACCINES MARKET VALUE FOR CONJUGATE VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 4. GLOBAL VACCINES MARKET VALUE FOR LIVE ATTENUATED VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 5. GLOBAL VACCINES MARKET VALUE FOR INACTIVATED VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 6. GLOBAL VACCINES MARKET VALUE FOR TOXOID VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 7. GLOBAL VACCINES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 8. GLOBAL VACCINES MARKET VALUE, BY INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 9. GLOBAL VACCINES MARKET VALUE FOR PNEUMOCOCCAL DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 10. GLOBAL VACCINES MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 11. GLOBAL VACCINES MARKET VALUE FOR HUMAN PAPILLOMAVIRUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 12. GLOBAL VACCINES MARKET VALUE FOR MENINGOCOCCAL DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 13. GLOBAL VACCINES MARKET VALUE FOR ROTAVIRUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 14. GLOBAL VACCINES MARKET VALUE FOR VARICELLA, MEASLES, MUMPS, & RUBELLA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 15. GLOBAL VACCINES MARKET VALUE FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 16. GLOBAL VACCINES MARKET VALUE FOR POLIO, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 17. GLOBAL VACCINES MARKET VALUE FOR HEPATITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 18. GLOBAL VACCINES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 19. GLOBAL VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 20. GLOBAL VACCINES MARKET VALUE FOR PEDIATRIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 21. GLOBAL VACCINES MARKET VALUE FOR ADULTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 22. GLOBAL VACCINES MARKET VALUE FOR TRAVELERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 23. NORTH AMERICA VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 24. NORTH AMERICA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 25. NORTH AMERICA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 26. NORTH AMERICA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 27. U.S VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 28. U.S VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 29. U.S VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 30. CANADA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 31. CANADA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 32. CANADA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 33. EUROPE VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 34. EUROPE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 35. EUROPE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 36. EUROPE VACCINES MARKET VALUE, END-USER, 2021-2027 (USD BILLION)
CHART. 37. GERMANY VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 38. GERMANY VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 39. GERMANY VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 40. U.K VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 41. U.K VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 42. U.K VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 43. FRANCE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 44. FRANCE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 45. FRANCE VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 46. ITALY VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 47. ITALY VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 48. ITALY VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 49. SPAIN VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 50. SPAIN VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 51. SPAIN VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 52. ROE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 53. ROE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 54. ROE VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 55. ASIA PACIFIC VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 56. ASIA PACIFIC VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 57. ASIA PACIFIC VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 58. ASIA PACIFIC VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 59. CHINA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 60. CHINA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 61. CHINA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 62. INDIA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 63. INDIA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 64. INDIA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 65. JAPAN VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 66. JAPAN VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 67. JAPAN VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 68. REST OF APAC VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 69. REST OF APAC VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 70. REST OF APAC VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 71. REST OF WORLD VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 72. REST OF WORLD VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 73. REST OF WORLD VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 1. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 2. GLOBAL VACCINES MARKET VALUE FOR RECOMBINANT, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 3. GLOBAL VACCINES MARKET VALUE FOR CONJUGATE VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 4. GLOBAL VACCINES MARKET VALUE FOR LIVE ATTENUATED VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 5. GLOBAL VACCINES MARKET VALUE FOR INACTIVATED VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 6. GLOBAL VACCINES MARKET VALUE FOR TOXOID VACCINES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 7. GLOBAL VACCINES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 8. GLOBAL VACCINES MARKET VALUE, BY INDICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 9. GLOBAL VACCINES MARKET VALUE FOR PNEUMOCOCCAL DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 10. GLOBAL VACCINES MARKET VALUE FOR INFLUENZA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 11. GLOBAL VACCINES MARKET VALUE FOR HUMAN PAPILLOMAVIRUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 12. GLOBAL VACCINES MARKET VALUE FOR MENINGOCOCCAL DISEASE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 13. GLOBAL VACCINES MARKET VALUE FOR ROTAVIRUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 14. GLOBAL VACCINES MARKET VALUE FOR VARICELLA, MEASLES, MUMPS, & RUBELLA, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 15. GLOBAL VACCINES MARKET VALUE FOR DIPHTHERIA, PERTUSSIS, & TETANUS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 16. GLOBAL VACCINES MARKET VALUE FOR POLIO, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 17. GLOBAL VACCINES MARKET VALUE FOR HEPATITIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 18. GLOBAL VACCINES MARKET VALUE FOR OTHERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 19. GLOBAL VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 20. GLOBAL VACCINES MARKET VALUE FOR PEDIATRIC, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 21. GLOBAL VACCINES MARKET VALUE FOR ADULTS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 22. GLOBAL VACCINES MARKET VALUE FOR TRAVELERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
CHART. 23. NORTH AMERICA VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 24. NORTH AMERICA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 25. NORTH AMERICA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 26. NORTH AMERICA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 27. U.S VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 28. U.S VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 29. U.S VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 30. CANADA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 31. CANADA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 32. CANADA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 33. EUROPE VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 34. EUROPE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 35. EUROPE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 36. EUROPE VACCINES MARKET VALUE, END-USER, 2021-2027 (USD BILLION)
CHART. 37. GERMANY VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 38. GERMANY VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 39. GERMANY VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 40. U.K VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 41. U.K VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 42. U.K VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 43. FRANCE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 44. FRANCE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 45. FRANCE VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 46. ITALY VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 47. ITALY VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 48. ITALY VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 49. SPAIN VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 50. SPAIN VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 51. SPAIN VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 52. ROE VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 53. ROE VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 54. ROE VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 55. ASIA PACIFIC VACCINES MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
CHART. 56. ASIA PACIFIC VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 57. ASIA PACIFIC VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 58. ASIA PACIFIC VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 59. CHINA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 60. CHINA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 61. CHINA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 62. INDIA VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 63. INDIA VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 64. INDIA VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 65. JAPAN VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 66. JAPAN VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 67. JAPAN VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 68. REST OF APAC VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 69. REST OF APAC VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 70. REST OF APAC VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
CHART. 71. REST OF WORLD VACCINES MARKET VALUE, BY TECHNOLOGY TYPE, 2021-2027 (USD BILLION)
CHART. 72. REST OF WORLD VACCINES MARKET VALUE, BY INDICATION, 2021-2027 (USD BILLION)
CHART. 73. REST OF WORLD VACCINES MARKET VALUE, BY END-USER, 2021-2027 (USD BILLION)
